Abbott Laboratories Corporation

Abbvie Inc.

Merck Sharp + Dohme Corp.

Other

Abbvie Deutschland Gmbh and Co Kg

Soumojeet Ghosh

Laman L Alani

Gunther Berndl

Bernd Liepold

Ulrich Reinhold

John M Lipari

Dilip Kaul

Joerg Breitenbach

Joerg Rosenberg

Rong R Gao

Kennan C Marsh

Laman A Al-Razzak

Vanik D Petrossian

Richard H Whelan

Donald P Gauwitz

Hing L Sham

Dale J Kempf

Daniel W Norbeck

Xiaoqi Chen

David A Betebenner

Thomas Kessler

Jörg Breitenbach

Jörg Rosenberg

Thomas R Herrin

Kevin Novak

John B Morris

Gondi N Kumar

Didier Lefebvre

Craig A McKelvey

Bhagwant Rege

Maria T Cruanes

Ashkan Kamali

Agam R Sheth

Jöerg Rosenberg

Monica Tijerina

Kyle A Fliszar

Jeorg Rosenberg

Bryan Wiesner

Jorg Breitenbach

Katja Fastnacht

Wolfgang Roth

Yan Cai

Laman A Alani

Joeerg Rosenberg

Craig A Mckelvey

Gunther Derndl

The present invention relates to a process for producing monolithic tablets. The method employs a melt-processed composition containing at least on active agent and at least one thermoplastic binder. The invention further relates to a method for cutting and deflashing a belt of pre-shaped bodies of a melt-processed composition, wherein the pre-shaped bodies are interconnected by flash.

Method for producing monolithic tablets

A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof. Pharmaceutical compositions of the invention include a flavoring system of the invention, a solvent system, and at least one pharmaceutically active agent, such as lopinavir or derivatives thereof, ritonavir or derivatives thereof, or mixtures thereof. Methods for making such liquid pharmaceutical compositions are also disclosed.

Flavoring systems for pharmaceutical compositions and methods of making such compositions

A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50&#xb0; C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Solid pharmaceutical dosage form

A liquid formulation for oral administration of the CETP inhibitor of formula (I) has improved bioavailability compared with conventional solid formulations. The formulation comprises the CETP inhibitor, or a pharmaceutically acceptable salt thereof; an oil; and one or more nonionic surfactants having a hydrophilic lipophilic balance (HLB)&#x3e;10. 

Self-emulsifying formulations of CETP inhibitors

Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.

Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin

The present invention provides a pharmaceutical dosage formulation, and more particularly, to a pharmaceutical dosage formulation comprising an HIV protease inhibitor.

Solid pharmaceutical dosage formulation

Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.

Pharmaceutical formulations

Growing community of inventors

Lansdale, PA, United States of America

Soumojeet Ghosh